UNIGE document Scientific Article
previous document  unige:7218  next document
add to browser collection

Treatment options of invasive fungal infections in adults

Fluckiger, Ursula
Marchetti, Oscar
Bille, Jacques
Zimmerli, Stefan
Imhof, Alexander
Ruef, Christian
show hidden authors show all authors [1 - 12]
Published in Swiss Medical Weekly. 2006, vol. 136, no. 29-30, p. 447-463
Abstract A panel of infectious disease specialists, clinical microbiologists and hospital epidemiologists of the five Swiss university hospitals reviewed the current literature on the treatment of invasive fungal infections in adults and formulated guidelines for the management of patients in Switzerland. For empirical therapy of Candida bloodstream infection, fluconazole is the drug of choice in non-neutropenic patients with no severe sepsis or septic shock or recent exposure to azoles. Amphotericin B deoxycholate or caspofungin would be the treatment option for patients with previous azole exposure. In neutropenic patients, empirical therapy with amphotericin B deoxycholate is considered first choice. In patients with severe sepsis and septic shock, caspofungin is the drug of first choice. For therapy of microbiologically-documented Candida infection, fluconazole is the drug of choice for infections due to C. albicans, C. tropicalis or C. parapsilosis. When infections are caused by C. glabrata or by C. krusei, caspofungin or amphotericin B deoxycholate are first line therapies. Treatment guidelines for invasive aspergillosis (IA) were stratified into primary therapy, salvage therapy and combination therapy in critically ill patients. Voriconazole is recommended for primary (ie upfront) therapy. Caspofungin, voriconazole (if not used for primary therapy) or liposomal amphotericin B are recommended for salvage therapy for refractory disease. Combination therapy with caspofungin plus voriconazole or liposomal amphotericin B should be considered in critically ill patients. Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events.
Keywords Antifungal Agents/adverse effects/ therapeutic useAspergillosis/ drug therapy/epidemiologyAzoles/therapeutic useCandidiasis/ drug therapy/epidemiologyClinical Trials as TopicDrug Therapy, CombinationEchinocandinsFungal Proteins/therapeutic useHumansPeptides, Cyclic/therapeutic usePolyenes/therapeutic useSwitzerland/epidemiology
PMID: 16937323
Full text
Research group Staphylocoques dorés résistants à la méthicilline et hygiène hospitalière (330)
(ISO format)
FLUCKIGER, Ursula et al. Treatment options of invasive fungal infections in adults. In: Swiss Medical Weekly, 2006, vol. 136, n° 29-30, p. 447-463. https://archive-ouverte.unige.ch/unige:7218

438 hits

0 download


Deposited on : 2010-06-21

Export document
Format :
Citation style :